🚀 VC round data is live in beta, check it out!
Innoviva Valuation Multiples
Discover revenue and EBITDA valuation multiples for Innoviva and similar public comparables like Sarepta Therapeutics, Zhejiang Jolly, Star Lake Bioscience, ANI Pharmaceuticals and more.
Innoviva Overview
About Innoviva
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.
Founded
1996
HQ
Employees
159
Website
Sectors
Financials (LTM)
EV
$1B
Innoviva Financials
Innoviva reported last 12-month revenue of $417M and EBITDA of $241M.
In the same LTM period, Innoviva generated $333M in gross profit, $241M in EBITDA, and $247M in net income.
Revenue (LTM)
Innoviva P&L
In the most recent fiscal year, Innoviva reported revenue of $411M and EBITDA of $370M.
Innoviva expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $417M | XXX | $411M | XXX | XXX | XXX |
| Gross Profit | $333M | XXX | $334M | XXX | XXX | XXX |
| Gross Margin | 80% | XXX | 81% | XXX | XXX | XXX |
| EBITDA | $241M | XXX | $370M | XXX | XXX | XXX |
| EBITDA Margin | 58% | XXX | 90% | XXX | XXX | XXX |
| EBIT Margin | 42% | XXX | 41% | XXX | XXX | XXX |
| Net Profit | $247M | XXX | $271M | XXX | XXX | XXX |
| Net Margin | 59% | XXX | 66% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Innoviva Stock Performance
Innoviva has current market cap of $2B, and enterprise value of $1B.
Market Cap Evolution
Innoviva's stock price is $22.83.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $2B | 0.0% | XXX | XXX | XXX | $3.63 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialInnoviva Valuation Multiples
Innoviva trades at 3.4x EV/Revenue multiple, and 6.0x EV/EBITDA.
EV / Revenue (LTM)
Innoviva Financial Valuation Multiples
As of March 21, 2026, Innoviva has market cap of $2B and EV of $1B.
Equity research analysts estimate Innoviva's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Innoviva has a P/E ratio of 6.9x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | 3.4x | XXX | 3.5x | XXX | XXX | XXX |
| EV/EBITDA | 6.0x | XXX | 3.9x | XXX | XXX | XXX |
| EV/EBIT | 8.3x | XXX | 8.5x | XXX | XXX | XXX |
| EV/Gross Profit | 4.3x | XXX | 4.3x | XXX | XXX | XXX |
| P/E | 6.9x | XXX | 6.3x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 7.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Innoviva Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Innoviva Margins & Growth Rates
Innoviva's revenue in the last 12 month grew by 8%.
Innoviva's revenue per employee in the last FY averaged $2.6M.
Innoviva's rule of 40 is 66% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Innoviva's rule of X is 78% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Innoviva Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Margin | 58% | XXX | 90% | XXX | XXX | XXX |
| EBITDA Growth | 15% | XXX | (25%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 66% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 78% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $2.6M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 28% | XXX | — | XXX | XXX | XXX |
| R&D Expenses to Revenue | 7% | XXX | 7% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 41% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Innoviva Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Sarepta Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Zhejiang Jolly | XXX | XXX | XXX | XXX | XXX | XXX |
| Star Lake Bioscience | XXX | XXX | XXX | XXX | XXX | XXX |
| ANI Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharvaris | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Innoviva M&A Activity
Innoviva acquired XXX companies to date.
Last acquisition by Innoviva was on XXXXXXXX, XXXXX. Innoviva acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Innoviva
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialInnoviva Investment Activity
Innoviva invested in XXX companies to date.
Innoviva made its latest investment on XXXXXXXX, XXXXX. Innoviva invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Innoviva
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Innoviva
| When was Innoviva founded? | Innoviva was founded in 1996. |
| Where is Innoviva headquartered? | Innoviva is headquartered in United States. |
| How many employees does Innoviva have? | As of today, Innoviva has over 159 employees. |
| Who is the CEO of Innoviva? | Innoviva's CEO is Pavel Raifeld. |
| Is Innoviva publicly listed? | Yes, Innoviva is a public company listed on Nasdaq. |
| What is the stock symbol of Innoviva? | Innoviva trades under INVA ticker. |
| When did Innoviva go public? | Innoviva went public in 2004. |
| Who are competitors of Innoviva? | Innoviva main competitors are Sarepta Therapeutics, Zhejiang Jolly, Star Lake Bioscience, ANI Pharmaceuticals. |
| What is the current market cap of Innoviva? | Innoviva's current market cap is $2B. |
| What is the current revenue of Innoviva? | Innoviva's last 12 months revenue is $417M. |
| What is the current revenue growth of Innoviva? | Innoviva revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of Innoviva? | Current revenue multiple of Innoviva is 3.4x. |
| Is Innoviva profitable? | Yes, Innoviva is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Innoviva? | Innoviva's last 12 months EBITDA is $241M. |
| What is Innoviva's EBITDA margin? | Innoviva's last 12 months EBITDA margin is 58%. |
| What is the current EV/EBITDA multiple of Innoviva? | Current EBITDA multiple of Innoviva is 6.0x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.